Data-driven Advanced Therapeutics Accelerator
It’s an accelerator programme designed and managed by Stevenage Bioscience Catalyst, focussed on data-enabled drug discovery and advanced therapies.
2021 Cohort
During the programme, 15 start-ups were selected to take part in an 18+ week virtual programme.
Training and mentoring were provided free of charge to help paticipants develop their ideas, build their skills and make the right contacts to move to the next phase.
-
A self-service analytics platform that empowers biologists to perform complex analysis and visualisation. -
Biotx.ai delivers predictive biomarkers as a basis for decision support in precision medicine. -
Enedra is harnessing the power of synthetic lethality and advanced computational Systems Biology to create therapeutics. -
Exogene is a biotechnology company accelerating the discovery of T-cell-receptor (TCR)- based cancer immunotherapies. -
GlamorousAI is AI-first preclinical biotech focusing on the discovery of novel chemistry for challenging targets. -
Human Centric Drug Discovery helps patients with central nervous disorders by making it easier to develop drugs for their diseases. -
iLoF is working to enable a new era of personalised medicine, by using AI and photonics to build a cloud-based ... -
Kantify has developed ZeptoNet - a novel AI technology that can perform in silico high-throughput screening... -
Micrographia Bio is a next generation life sciences company focused on applying machine learning to microscopy. -
Oppilotech have developed a high-resolution platform based on systems biology and machine learning to model biological processes. -
The first flexible, open platform built for scientists. Structured experimental data, analytics and lab management. -
Rahko is unlocking quantum drug discovery. Drug discovery is slow, expensive and low precision. -
With the primary focus in Parkinson’s disease, Solvemed Group leverages its proprietary machine learning technology. -
Svastia offers clinical decision support for cancer treatment selection and relapse prediction. -
Following tumour exome sequencing, Vivan Therapeutics generates fruit fly avatars of patients incorporating tumourigenic mutations.
Learn directly from specialists in your field.
Find out moreCopyright © 2022 Stevenage Bioscience Catalyst
We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.